We present the rationale and study design of the CGMT (combined gefitinib and metformin therapy) trial (www. ClinicalTrials.gov Identifier: NCT01864681), which is aimed at treating locally advanced nonesmall-cell lung cancer. The CGMT trial is a multicenter, phase II randomized, double-blinded, and placebo-controlled study, which is designed to evaluate the safety and efficacy of metformin in combination with gefitinib as first-line therapy in patients presenting with stage IIIb-IV nonesmall-cell lung cancer expressing the epidermal growth factor receptor mutant. Two therapies are proposed for this trial. The first regimen is comprised of gefitinib plus metformin. The second therapy is comprised of gefitinib plus placebo. The primary objective of this trail is to compare the progression-free survival rate at year 1 of the study. The secondary objective of this trial is to compare the 2-year overall survival, the 2-year progression-free survival, the objective response rate, and the disease-control rate, and to evaluate the relative safety of both therapies. Based on the statistical design, we plan to enroll approximately 200 patients.
Introduction
Nonesmall-cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the world. 1 However, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) is a standard first-line therapy for patients presenting with advanced EGFR mutant-expressing NSCLC. However, after a median of 10 months, most patients develop clinical evidence of acquired resistance to EGFR-TKI. 2 The contributing mechanisms responsible for the EGFR-TKI resistance include: secondary mutations of EGFR (eg, T790M in exon 20), 3 amplification of MET, 4 activation of phosphatidylinositol-3 kinase (PI3K)/Akt pathways, 5, 6 and constitutive activation of JAK2/STAT3. 7, 8 A number of treatment strategies have been considered in overcoming acquired resistance. For example, a number of studies applied the combinatorial therapy of EGFR-TKI and pathway inhibitors, including inhibitors for HER2, 9 IGF-1R, 10 PI3K, 11 and mTOR, 12 which improved the therapeutic effect as compared with using EGFR-TKI alone. However, these inhibitors display high toxicity and are very expensive, which adds to the difficulty of using them clinically. Another method involves therapeutic rechallenge with a combination of EGFR-TKI and bevacizumab after acquired resistance e a system that can achieve satisfactory therapeutic efficacy. 13 However, these strategies are costly and/or have serious side effects and are thus not amenable for large-scale application. It is an urgent need to identify a treatment strategy that is less expensive and displays fewer side effects. To this point, scientists have attempted to discover a therapeutic agent that is safe, inexpensive, and, most importantly, can enhance the anti-tumor effect of EGFR-TKI and delay the onset and development of drug resistance. Metformin (N 0 , N 0 -dimethylbiguanide) is a member of the biguanide class of oral hypoglycemic agents, and might represent a good candidate in the therapy of NSCLC. Metformin is an antidiabetic prescription drug that is widely used in the treatment of type II diabetes. 14 A series of studies have previously shown that metformin has an auxiliary anti-tumor function. 15, 16 Further studies have shown that metformin is not only synergistic with standard chemotherapy, but is also closely associated with EGFR-TKI therapeutics. It has been shown in a number of studies that metformin combined with gefitinib can reduce tumor proliferation and colony-forming ability and has significant pro-apoptotic effect against NSCLC cell lines in general, and against NSCLC cell lines that are resistant to EGFR-TKI. 17, 18 A study that was previously conducted by our group also showed that metformin can effectively increase the sensitivity of TKI-resistant lung cancer cells to erlotinib or gefitinib. 19 In addition, our retrospective clinical study on patients with lung cancer that co-presented with diabetes and EGFR gene mutations showed that metformin combined with EGFR-TKI therapy displays a much improved progression-free and overall survival than those treated with EGFR-TKI or other hypoglycemic agents alone. 20 Moreover, we have previously found that combined use of metformin and gefitinib could attenuate gefitinib-induced pulmonary fibrosis, which is a rare but deadly side effect. 21 Metformin decreases serum glucose levels by inhibiting gluconeogenesis in the liver; thus, it does not influence serum glucose levels in healthy adults. Furthermore, metformin is metabolized independently of the liver, and is excreted through the renal tubule in its original form, so that it does not influence the functions of either the liver or the kidney. Thus, the combined use of metformin and EGFR-TKI could achieve a higher level of anti-cancer efficacy for patients with lung cancer. The above-mentioned evidence encouraged our group to design a combined gefitinib and metformin therapy (CGMT) trial to examine the effects and safety of a combined treatment of metformin with gefitinib as first-line therapy for NSCLC that expressed an EGFR mutation. Another ongoing trial METformin in Advanced Lung cancer (METAL) conducted by Fasano et al, also attempted to investigate the effect of metformin with EGFR-TKI on advanced NSCLC. 22 Indeed, both CGMT and METAL have 2 points in common. The first is that both studies adopt the same treatment strategy, which is the combination of metformin with EGFR-TKI in treating patients with advanced NSCLC. The second is that both studies have attempted to identify whether metformin and EGFR-TKI synergize in the therapeutic targeting of patients with lung cancer that do not co-present with diabetes. However, METAL is focused on second-line therapy of advanced NSCLC, whereas first-line chemotherapy may influence the condition of the patient and thus affect the cooperative effect of metformin with gefitinib. Moreover, it is difficult to differentiate between the therapeutic effect of EGFR-TKI when combined with metformin in the second-line therapy of NSCLC and that of firstline chemotherapy.
The CGMT study has the following highlighted characteristics: (1) CGMT has a target of recruiting 200 subjects, and will adopt a dose-escalation scheme of metformin, starting with a dose of 500 mg twice a day, increasing to 1000 mg twice daily. Clinically, the recommended dose of metformin is 500 to 2550 mg per day, with an optimal working dose of 2000 mg per day. We used a dose of 2000 mg per day, and started with a low dose and sequentially increased the dose in the study. Furthermore, we focused on firstline therapy of patients with advanced NSCLC who exhibited EGFR mutations. According to the National Comprehensive Cancer Network NSCLC Guidelines, EGFR-TKI therapy is recommended as first-line treatment for advanced NSCLC with expression of EGFR mutations. First-line addition of metformin with gefitinib can rule out other factors during therapy, including multi-line therapies, which may influence the effectiveness of metformin. Thus, the combination of metformin and gefitinib in firstline therapy would benefit the patients most. (2) The CGMT study chose gefitinib, not erlotinib, in combination with metformin. Evidence shows that metformin exerts an impact on the activity of CYP3A4, which is a highly important and well-studied target gene of the pregnane X receptor. The pregnane X receptor is the crucial drug/xenobiotic enzyme that metabolizes about 50 percent of all drugs and xenobiotics. 23 Thus, metformin can increase the blood concentration of TKI therapy. The effective dose of gefitinib is much lower than its maximum tolerated dose (MTD), whereas the effective dose of erlotinib is almost the same as its MTD. Consequently, the combination of metformin and erlotinib at the regular dose may increase the effective concentration of erlotinib in vivo, probably above that of the MTD of erlotinib, which may increase the risk of serious side effects. Although the combination of metformin and gefitinib at conventional doses will also increase the dose of gefitinib in vivo, the dose is lower than its MTD, which would decrease the risk of serious side effects. In addition, an increase in the dose of gefitinib could improve both therapeutic efficacy and inhibition of drug resistance. 24 In this context, our combinatorial strategy is more clinically feasible. This is why we choose the combination of gefitinib and metformin and not a combination of erlotinib and metformin. (3) For safety issues, metformin might result in lactic acidosis in patients with renal function disorders or hypoxia, whereas patients with advanced age or adverse conditions are excluded from the current trial. Indeed, there are currently more than 200 clinical trials applying metformin in nondiabetic patients that present with cancer. In addition, metformin has long been used in patients with polycystic ovary syndrome 25 ; thus, the use of metformin in nondiabetic patients is safe and complies with ethical requirements.
Objectives
This study will investigate whether metformin in combination with gefitinib is effective in patients with previously untreated advanced or metastatic NSCLC that harbor EGFR mutations.
Criteria
Study entry is limited to patients aged > 18 years and < 75 years of age with histologically or cytologically confirmed NSCLC that have measurable stage IIIb to IV disease (including M1a, M1b stages or recurrent disease) that was previously untreated and harbors EGFR mutations with a life expectancy of greater than 12 weeks, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients must also have normal organ and marrow function.
The main exclusion criteria include uncontrolled concurrent illness; type 1 or 2 diabetes; impaired glucose tolerance; therapeutic anticoagulation, chemotherapy, immunotherapy, hormonal therapy, and radiotherapy within 2 weeks of the commencement of the study; uncontrolled brain metastasis; and HIV-positive status on combined antiretroviral therapy. Institutional review boardapproved informed consent will be obtained from every patient before initiation of any trial-specific procedure or treatment.
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Treatment Plan
The sample size (200 subjects) is based on the "Sample Size Calculation for Log-rank Test" proposed by Schoenfeld, 26 together with a 10% expulsion rate. The 200 subjects are randomly selected at the rate of 1:1 through the CIMS-Central Randomization System, with 100 subjects in each group. In the experimental group of our study, gefitinib and metformin are administered, whereas gefitinib and placebo are administered in the control group (Figure 1 ). The exact administration in the experimental group is as follows: metformin is initiated at a dose of 500 mg twice per day, and administered orally with meals. After 1 week of being on study, the dose of metformin is increased to 1000 mg as the first dose of the day and 500 mg as the second dose of the day. After another week, metformin is increased to1000 mg and is administered twice per day. The administration in the control group is as follows: placebo is given to patients in the same way as that of metformin in the experimental group. Further, maintenance therapy of patients responding to therapy will be maintained with metformin therapy given at a dose of 1000 mg twice daily, co-administered with gefitinib. In the absence of treatment delays owing to adverse events, treatment may continue until one of the following criteria applies: (1) Disease progression; (2) Concurrent illness that prevents further administration of treatment; (3) Unacceptable adverse events(s); (4) Patient decides to withdraw from the study; or (5) General or specific changes in the condition of the patient that render the patient unacceptable for further treatment in the judgment of the investigator.
Expected Results and Toxicities
The primary and secondary end-point analyses were performed in accordance with the intention-to-treat population. All adverse events and abnormal laboratory variables were reported and graded in accordance with the National Cancer Institute's Common Terminology Criteria, version 4.0.
Conclusions
The CGMT trial is expected to meet its primary objective, which is to demonstrate a significant improvement in the median progression-free survival during first-line treatment in this disease setting, and displaying minimal effects on the quality of life. The trial was started during July 2013, and since that time, we have enrolled more than 180 patients that were recruited from more than 10 Grade 3A hospitals across China. In addition, some patients had taken the treatment plan for more than 1 year, and thus far, none of the patients have reported any severe adverse events.
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